Novo Nordisk (NOVO) CMD 2026 summary

Strategic ambitions for 2030

• Strategy centers on strengthening diabetes and obesity, diversifying into blood, endocrine, liver and cardiovascular diseases, and pursuing consumer Rx opportunities.

• 2026–30 revenue CAGR targeted at least in line with pharma peers, described as mid-single-digit growth; operating margin aimed to remain broadly stable.

• Plan to launch at least 10 Phase III programs, split between diabetes and obesity and other areas, and more than five multi-blockbusters by 2030.

• Risk-adjusted pipeline value targeted to exceed DKK 150bn in less than 10 years, excluding business development and consumer Rx; pipeline sales ambition exceeds DKK 150bn by 2035.

• Aim to serve more than 60m patients by 2030 and emerge from semaglutide loss of exclusivity as a larger, more diversified business.

Research and development

• First human doses rose from three in 2025 to five so far in 2026; at least 10 are targeted this year, with current potential of 15–16 after attrition.

• Target at least 15 first human doses annually from 2027 through 2030 and more than 20 annually beyond 2030; diabetes and obesity submissions aimed within five years of first human dose.

• At least eight Phase II trials in novel disease areas planned over the next year, including immune-mediated inflammatory disease, pain and addiction, and women's and men's health.

• At least five oral assets targeted in clinical development by year-end; oral and injectable options aim to address efficacy, tolerability, convenience and affordability.

• AI is embedded across R&D: target hit rate improved threefold, while an amylin discovery effort achieved 500-fold potency improvement in three design rounds over ~three months.

Diabetes and obesity portfolio

• CagriSema obesity launch targeted for early 2027, subject to approval; cagrilintide monotherapy potential launch in 2028, followed by higher-dose CagriSema a year later.

• CagriSema showed 23% weight loss in REDEFINE 1; REDEFINE 11 data expected in Q1 2027 and high-dose data during 2028.

• In type 2 diabetes, REIMAGINE 5 showed 12.5% weight loss with CagriSema versus 9% with comparator at studied doses, with similar glycemic control; launch targeted in 2028.

• Oral zenagamtide is intended to launch alongside its injectable version with similar labels; the oral program plans five maintenance doses for individualized treatment.

• Wegovy pill capacity targeted at 10x the current 1.5m patients by 2030; oral GLP-1 capacity ambition is to serve 10x more people with obesity.